Abstract:
Human African Trypanosomiasis (HAT), a once largely forgotten disease, is back on the agenda. A public-private partnership between the World Health Organization (WHO), pharmaceutical companies and international donors succeeded in curbing the recent epidemic, but active transmission is still ongoing in several countries. The burden of the disease in affected individuals is high. Untreated the disease is always fatal and estimates of the Disability Adjusted Life Years (DALYs) lost per premature death range from 25 to 33 years. Even for successfully treated patients, the burden on households and livelihoods is high – between 1.5 and 10 months’ income, even when diagnostics and HAT drugs are provided for free. Costs ranging from $10–17 per DALY averted for case-finding and treatment places the control of T.b. gambiense HAT firmly in the category of highly cost-effective health interventions.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- DALY:
-
disability adjusted life year
- DRC:
-
democratic republic of Congo
- HAT:
-
Human African Trypanosomiasis
- NGO:
-
Non-Governmental Organization
- T.b.:
- WHO:
-
World Health Organization
- YLL:
-
years of life lost
References
Fèvre EM, Odiit M, Coleman PG, Woolhouse ME, Welburn SC. (2008). BMC Public Health. 8: 96.
Fèvre EM, Picozzi K, Fyfe J, Waiswa C, Odiit M, Coleman PG, Welburn SC. (2005). Lancet. 366: 745–747.
Goodwin C, Coleman P, Mills A. (2000). Economic Analysis of Malaria Control in Sub-Saharan Africa. Global Forum for Health Research, Geneva, Switzerland.
Gouteux JP, Bansimba P, Noireau F, Frézil JL (1987). Med Trop. 47: 61–63.
Gouteux JP, Sinda D. (1990). Trop Med Parasitol. 41: 49–55.
Lancien J. (1991). Ann Soc Belg Méd Trop. 71 (Suppl. 1): 35–47.
Laveissiére C, Grébaut P, Lemasson J. (1994). Les communautés rurales et la lutte contre la maladie du sommeil en forêt de Côte-d’Ivoire, WHO/TRY/94.1, Genève.
Lutumba P, Makieya E, Shaw A, Meheus F, Boelaert M. (2007a). Emerg Infect Dis. 13: 248–254.
Lutumba P, Meheus F, Robays J, Miaka C, Kande V, Buscher P, Dujardin B, Boelaert M. (2007b). Emerg Infect Dis. 13: 1484–1490.
Lutumba P, Robays J, Miaka mia BC, Mesu VK, Molisho D, Declercq J, Van der Veken W, Meheus F, Jannin J, Boelaert M. (2005). Emerg Infect Dis. 11: 1382–1389.
Moore A, Richer M. (2001). Trop Med Int Health. 6: 342–347.
Moore A, Richer M, Enrile M, Losio E, Roberts J, Levy D. (1999). Am J Trop Med Hyg. 61: 315–318.
Odiit M. (2003). The Epidemiology of Trypanosoma brucei rhodesiense in Eastern Uganda. Unpublished PhD thesis, University of Edinburgh, pp. 210.
Odiit M, Coleman PG, Liu WC, McDermott JJ, Fèvre EM, Welburn SC, Woolhouse ME. (2005). Trop Med. Int Health. 10: 840–849.
Odiit M, Shaw A, Welburn SC, Fèvre EM, Coleman PG, McDermott JJ. (2004). Ann Trop Med Parasitol. 98: 339–348.
Politi C, Carrin G, Evans D, Kuzoe FA, Cattand PD. (1995). Health Econ. 4: 273–287.
Priotto G, Pinoges L, Fursa IB, Burke B, Nicolay N, Grillet G, Hewison C, Balasegaram M. (2008). BMJ. 336: 705–708.
Robays J, Bilengue MM, Van der SP, Boelaert M. (2004). Trop Med Int Health. 9: 542–550.
Robays J, Raguenaud ME, Josenando T, Boelaert M. (2008). Trop Med Int Health. Feb; 13(2): 265–271.
Schmid C, Shaw A, Santercole C, Kwete J, Lutumba P, Burri C. (2004). In: Schmid C. (2004) 10-Day Melarsoprol Treatment of Trypanosoma brucei gambiense Sleeping Sickness. PhD Thesis, University of Basel. Basler Schnelldruck, Basel.
Shaw AP. (1989). Ann Soc Belg Med Trop. 69 (Suppl. 1): 237–253.
Shaw AP, Cattand P. (2001). Med Trop (Mars). 61: 412–421.
Shaw APM. (2004). In: Maudlin I, Holmes PH, Miles MA (eds.). The Trypanosomiases. CAB International, Wallingford, UK, pp. 369–402.
Simarro PP, Sima FO, Mir M, Mateo MJ, Roche J. (1991). Bull World Health Organ. 69: 451–457.
Trowbridge M, McFarland D, Richer M, Adeoye M, Moore A. (2001). Am J Trop Med Hyg. 62 (3 Suppl.): 312.
Van Nieuwenhove S, Betu-Ku-Mesu VK, Diabakana PM, Declercq J, Bilengé CM. (2001). Trop Med Int Health. 6: 335–341.
Welburn SC, Fèvre EM, Coleman PG, Odiit M, Maudlin I. (2001). Trends Parasitol. 17: 19–24.
WHO. (1998). World Health Organ Tech. Rep. Ser. 881: I-114.
WHO. (2000) WHO Report on Global Surveillance of Epidemic-prone Infectious Diseases. WHO Department of Communicable Disease Surveillance and Response, WHO/CDS/CSR/ISR/2000.1.
WHO. (2004) Wkly Epidemiol Rec. 79: 297–300.
WHO. (2006) Wkly Epidemiol Rec. 81: 71–80.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Appendix
Appendix
Key Facts for Human African Trypanosomiasis (HAT)
-
HAT is transmitted by tsetse flies.
-
There are two forms of the disease. In East Africa HAT presents as an acute syndrome caused by T.b. rhodesiense, and is maintained by an animal reservoir. West African HAT is caused by T.b. gambiense, has a much more protracted course than East African HAT and is transmitted in a man-fly-man cycle. The role of an animal reservoir still needs to be clarified.
-
There are two stages of the disease, an early stage (hemolymphatic stage), with few or aspecific symptoms, and a late (meningo-encephalitic) stage.
-
Main symptoms of HAT are neuro-psychiatric, including behavioral problems, personality disorders, sleep disturbances and coma. It almost invariably results in death, if left untreated.
-
Treatment of patients in the meningo-encephalitic stage requires more expensive and toxic drugs. Melarsoprol, still the most commonly used drug for second stage, kills between 5 and 10% of the patients. The only alternative, eflornithine, is expensive and difficult to administer.
-
Ninety percent of HAT cases in the world are caused by T.b. gambiense. T.b. gambiense often occurs in epidemics. Active case finding conducted by mobile teams has been the cornerstone of the control of HAT since colonial times.
-
If treated at a late stage, sequelae, mainly persistence of personality disorders and decreased mental capacities, are very frequent and pose a huge burden on the community long after the HAT epidemics are brought under control.
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media LLC
About this entry
Cite this entry
Shaw, A., Robays, J., Fèvre, E.M., Lutumba, P., Boelaert, M. (2010). The Burden of Human African Trypanosomiasis. In: Preedy, V.R., Watson, R.R. (eds) Handbook of Disease Burdens and Quality of Life Measures. Springer, New York, NY. https://doi.org/10.1007/978-0-387-78665-0_83
Download citation
DOI: https://doi.org/10.1007/978-0-387-78665-0_83
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-78664-3
Online ISBN: 978-0-387-78665-0
eBook Packages: MedicineReference Module Medicine